Response Genetics (RGDX -2.7%) says it's reached its second milestone payment hurdle in conjunction with a licensing agreement with GlaxoSmithKline (GSK) signed in 2010 to develop its BRAF-Inhibitor Tafinlar. Under the terms of the agreement, GSK gained certain rights to Response Genetics' proprietary PCR analysis technology and diagnostic expertise which received premarket approval from the FDA in May.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs